We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

New Technology Quantitatively Analyzes Alzheimer's Biomarkers Using MR and PET Images

By MedImaging International staff writers
Posted on 21 Jul 2023
Print article
Image: Neurophet AQUA is an AI-based degenerative brain disease diagnosis assistant software (Photo courtesy of Neurophet)
Image: Neurophet AQUA is an AI-based degenerative brain disease diagnosis assistant software (Photo courtesy of Neurophet)

A novel treatment for Alzheimer's disease utilizes an anti-amyloid antibody drug to reduce amyloid beta proteins in the brain. However, a common side effect, ARIA (Amyloid-Related Imaging Abnormalities), often appears in brain scans of patients using the drug. Therefore, careful monitoring and management of ARIA is crucial when prescribing anti-amyloid antibody drugs. Now, new cutting-edge brain imaging solutions for Alzheimer's disease treatment can enable the analysis of ARIA, thereby improving efficacy and outcomes.

Neurophet (Seoul, South Korea), an artificial intelligence (AI) solution company specializing in brain diseases, has developed a new technology to examine ARIA-E (edema) typically detected by T2-FLAIR, an MRI sequence, and ARIA-H (hemorrhages), primarily identified by GRE or SWI. An amyloid-PET scan is necessary to observe cortical amyloid beta deposition. Neurophet’s advanced technology predicts amyloid positivity through MR images before conducting amyloid-PET scans. The use of MR images for predicting amyloid positivity could provide a cost-effective solution for clinical trials and prognosis monitoring of Alzheimer's disease treatment, given that amyloid-PET scans are costly and their use and reimbursement are severely restricted. Moreover, PET scans are not universally accessible due to the limited availability of PET scanners.

At the recent Alzheimer's Association International Conference (AAIC) 2023, Neurophet showcased its cutting-edge brain imaging analysis technology, which can be applied in clinical trials and the prescription of new Alzheimer's disease drugs. The company's Neurophet AQUA software, a brain MRI analysis tool, analyzes brain atrophy observed in neurodegenerative diseases like Alzheimer's. Another product, the Neurophet SCALE PET software, quantitatively assesses Alzheimer's disease biomarkers using MR and PET images. It provides quantitative measurement of cortical amyloid beta deposition, a known causative agent of Alzheimer's disease. Neurophet is investing in research and development of analysis technology for ARIA side effects and aims to bring the products to market along with the launch of new Alzheimer's disease treatments.

"Neurophet's major products and technologies are expected to be very useful in the process of clinical trials, diagnosis, side effect monitoring and prognosis observation of Alzheimer's disease treatment." said CEO Jake Junkil Been of Neurophet. "We are going all out to develop solutions related to Alzheimer's disease treatment to preemptively target the high-growth Alzheimer's disease treatment market."

Related Links:

Gold Member
Solid State Kv/Dose Multi-Sensor
Mobile Digital X-Ray System
Ultrasound Color LCD
Drape Barrier
Double Pivot Swing Arm Drape

Print article



view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Calantic Digital Solutions is an orchestrated suite of AI radiology solutions that aims to transform radiology (Photo courtesy of Bayer)

Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions

Imaging data constitutes approximately 90% of all medical data, with the volume of such data continuously expanding, thereby significantly increasing the workload for radiologists amid existing resource limitations.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.